循环肿瘤DNA中的表皮生长因子受体突变 - Suppr

Suppr

超能文献

EGFR mutations in circulating tumour DNA.

作者信息

Rosell Rafael, Molina Miguel Angel, Serrano María Jose

机构信息

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

出版信息

Lancet Oncol. 2012 Oct;13(10):971-3. doi: 10.1016/S1470-2045(12)70369-8.

DOI:10.1016/S1470-2045(12)70369-8

PMID:23026821

Abstract

摘要

相似文献

EGFR mutations in circulating tumour DNA.

Lancet Oncol. 2012 Oct;13(10):971-3. doi: 10.1016/S1470-2045(12)70369-8.

Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.

Cancer Genet. 2013 Mar;206(3):73-80. doi: 10.1016/j.cancergen.2013.01.005. Epub 2013 Mar 9.

Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.

Anticancer Res. 2012 Aug;32(8):3339-44.

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.

Clin Cancer Res. 2011 Dec 15;17(24):7808-15. doi: 10.1158/1078-0432.CCR-11-1712. Epub 2011 Oct 5.

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Clin Cancer Res. 2006 Jul 1;12(13):3915-21. doi: 10.1158/1078-0432.CCR-05-2324.

Significance of EGFR Expression in Circulating Tumor Cells.

Adv Exp Med Biol. 2017;994:285-296. doi: 10.1007/978-3-319-55947-6_16.

Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay.

Clin Cancer Res. 2000 Apr;6(4):1439-44.

Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.

Hum Pathol. 2006 Jun;37(6):755-63. doi: 10.1016/j.humpath.2006.02.004.

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.

Br J Cancer. 2006 Nov 20;95(10):1390-5. doi: 10.1038/sj.bjc.6603428. Epub 2006 Oct 24.

Avoiding introduction of bias in the analysis of the methylation of free circulating DNA.

Clin Chim Acta. 2015 Apr 15;444:206-7. doi: 10.1016/j.cca.2015.02.020. Epub 2015 Feb 14.

引用本文的文献

Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.

Cancer Chemother Pharmacol. 2020 Mar;85(3):525-535. doi: 10.1007/s00280-019-04008-9. Epub 2019 Dec 12.

Targeting EGFR in Lung Cancer: Current Standards and Developments.

Drugs. 2018 Jun;78(9):893-911. doi: 10.1007/s40265-018-0916-4.

Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1364-S1372. doi: 10.21037/jtd.2017.09.59.

Liquid Biopsy in Non-Small Cell Lung Cancer.

Front Med (Lausanne). 2016 Dec 23;3:69. doi: 10.3389/fmed.2016.00069. eCollection 2016.

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.

Clin Lung Cancer. 2017 Jan;18(1):60-67. doi: 10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28.

Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

Transl Lung Cancer Res. 2016 Oct;5(5):466-482. doi: 10.21037/tlcr.2016.10.02.

Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Transl Lung Cancer Res. 2016 Oct;5(5):455-465. doi: 10.21037/tlcr.2016.10.07.

Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Elife. 2016 Feb 23;5:e09462. doi: 10.7554/eLife.09462.

Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Ann Transl Med. 2014 Nov;2(11):107. doi: 10.3978/j.issn.2305-5839.2014.08.11.

Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

Target Oncol. 2015 Jun;10(2):247-53. doi: 10.1007/s11523-014-0332-y. Epub 2014 Aug 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验